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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYDysfunction of the specialized cardiac conduction system (CCS) is associated with life-threatening arrhythmias. Strategies to derive CCS
cells, including rare Purkinje cells (PCs), would facilitatemodels for mechanistic studies and drug discovery and also provide new cellular
materials for regenerative therapies. A high-throughput chemical screen using CCS:lacz and Contactin2:egfp (Cntn2:egfp) reporter embry-
onic stem cell (ESC) lines was used to discover a small molecule, sodium nitroprusside (SN), that efficiently promotes the generation of
cardiac cells that express gene profiles and generate action potentials of PC-like cells. Imaging and mechanistic studies suggest that SN
promotes the generation of PCs from cardiac progenitors initially expressing cardiacmyosin heavy chain and that it does so by activating
cyclic AMP signaling. These findings provide a strategy to derive scalable PCs, alongwith insight into the ontogeny of CCS development.INTRODUCTION
The cardiac conduction system (CCS) is composed of the
impulse-generating sino-atrial (SA) and atrio-ventricular
(AV) nodes and the impulse-propagating His-Purkinje
system, which play critical roles initiating and regulating
excitation and contraction of the cardiac chambers.
Dysfunction of the CCS caused by disease, congenital mal-
formations, aging, or heritable gene defects results in car-
diac arrhythmias, a major cause ofmorbidity andmortality
worldwide (Spooner et al., 2001). Current treatments of
cardiac arrhythmias include pharmacological therapy and
implantable rhythm-management devices, such as pace-
makers and defibrillators. However, these treatments can
have low efficacy and also cause additional problems,
such as pro-arrhythmia side effects, infection, and device
malfunction (Holzmeister and Leclercq, 2011; Woods and
Olgin, 2014). Devices placed into pediatric patients must
be replaced as heart development proceeds throughout
life. Thus, there is a clear and compelling need to develop
strategies to treat patients with CCS defects.
Genetic and cell-based therapeutic approaches have
focused on generation of biological pacemakers (Cho and
Marba´n, 2010; Rosen et al., 2004). Embryonic stem cells
(ESCs) are a feasible starting material, as they are pluripo-
tent and can be differentiated to any cell lineage. Several
ESC reporter lines have been engineered and used to isolate
CCS cells, including (1) HCN4p-EGFP+ cells that express
transcripts for CCS markers Hcn4, Cav3.2, and Cx40 and
display a hyperpolarization-activated depolarizing current
(termed the funny current; Morikawa et al., 2010); (2) an
ESC reporter line containing aMink:lacz transgene and a re-
porter regulated by a chicken Gata6 (cGata6) enhancer; theStem Cdouble-positive cells display pacemaker-like morphology
and show pacemaking action potential waveform as well
as a funny current (White and Claycomb, 2005); (3) a
Shox2 promoter with a Cx30.2 enhancer to generate ESC-
derived SHOX2+ and Cx30.2+ cardiomyocytes that express
additional CCS markers (Hcn4, Cx45, Cx30.2, Tbx2, and
Tbx3) and exhibit pacemaker-nodal phenotype (Hashem
and Claycomb, 2013); (4) ESC-derived Nkx2.5:GFP+ cells
expressing Hcn1 and Hcn4 that display the funny current
(Yano et al., 2008); and (5) an ESC reporter line derived
from Contactin2:EGFP BAC transgenic mice (Cntn2:egfp)
was recently used to isolate rare cells that display transcrip-
tional signatures and functional properties comparable to
endogenous cardiac Purkinje cells (PCs) (Maass et al.,
2015). Finally, CD166 has been identified as a CCS cell-sur-
facemarker (Scavone et al., 2013), although it is not specific
to CCS constituents.
ESCs can also be directed into CCS-like cells using
chemicals and small-molecule compounds. For example,
vitamin B12 promoted the expression of CCS markers
Cx40 and Hcn4 at an early stage of cardiomyocyte differen-
tiation (Saito et al., 2009). Treating ESCs with Ca2+-acti-
vated potassium channel (SKCa) activator, 1-ethyl-2-benzi-
midazolinone (EBIO), or suramin promoted a nodal-like
cell phenotype (Kleger et al., 2010; Wiese et al., 2011).
Hence, cell-permeable small molecules that modulate
functions of specific pathways provide a convenient and
efficient approach to control stem/progenitor cell fate.
Importantly, these small molecules provide new tools to
dissect molecular mechanisms that control embryonic
development, therefore facilitating a better understanding
for functions of relevant signaling pathways. However,
overall efficiency of generating CCS cells using any of theell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The Authors 1089
current protocols is poor (typically below 1% of the cul-
ture). Thus, developing an efficient strategy to derive CCS
cells will not only facilitate developing disease models for
mechanistic studies and drug discovery but also provide
new cellular materials for regenerative therapy.
Here, we describe a high-throughput screen of 5,000
compounds using an ESC line derived from theCCS:lacz re-
porter mouse, containing a transgene that fortuitously
marks cells of the CCS lineage (Rentschler et al., 2001).
We discovered that the small molecule sodium nitroprus-
side (SN) efficiently enhances the generation of CCS cells
from ESCs. The screen was validated using an additional re-
porter line, with GFP expression driven by a Contactin2
(Cntn2) transgene (Maass et al., 2015). The derived GFP+
cells induced by SN display an expression profile, molecu-
lar markers, and functional properties that are comparable
to endogenous PC of the ventricular CCS. Importantly, we
found that SN promotes the generation of PC-like cells
through activating cyclic AMP (cAMP) signaling in embry-
onic cardiac cells, providing new insight into the ontogeny
of CCS lineages.RESULTS
A High-Throughput Screen to Identify Compounds
that Promote CCS Fate
The ESC reporter line CCS:Laczwas used to screen for small
molecules that promote the generation of CCS cells, in the
context of a directed differentiation assay. This reporter
line was derived from theCCS:Lacz transgenicmouse strain
carrying a b-galactosidase (Lacz) reporter gene that had
randomly inserted near the Slco3A1 locus and that shows
robust b-galactosidase expression in all cells of the devel-
oping and mature CCS, including the SA node, AV node,
His bundle, bundle branches, and Purkinje fibers (Rent-
schler et al., 2001; Stroud et al., 2007). Since CCS compo-
nents are derived from cardiac progenitors (Laflamme
and Murry, 2011), the first step of the assay was to direct
the ESCs toward commitment of cardiac mesoderm. Car-
diac progenitors are marked by co-expression of FLK1
(KDR, VEGFR2) and PDGFR-a, which is enhanced in
the presence of optimized levels of the growth factors
BMP4 and ACTIVIN-A (Kattman et al., 2011). Therefore,
cytokine induction conditions were first established for
the CCS:Lacz ESC line, in which the double-positive
(FLK1+ and PDGFR-a+) cell population was efficiently
induced (Figure S1). The line was then used to screen under
these conditions for subsequent enhanced generation of
LacZ expression (see Figure 1A and the Experimental Proce-
dures for details of the assay).
To performhigh throughput screening, we added a single
compound from a library containing 4,880 chemicals to1090 Stem Cell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The Auteach well in a 384-well format. The library is composed
of annotated compounds including signaling pathway reg-
ulators, kinase inhibitors, and Food and Drug Administra-
tion (FDA)-approved drugs. Cells were screened at two
concentrations for each compound (10 mM or 1 mM).
After 5 days of chemical treatment, cells were lysed to quan-
tify b-galactosidase activity relative to cells treated with
DMSO alone, which served as negative controls. 96 com-
pounds caused at least a 2.5-fold increase in b-galactosidase
activity compared to DMSO controls and were chosen as
primary hits for further analysis (Figure S1). We focused
on 15 primary-hit compounds that had effects under
10 mM(Table S1), and these were re-examined using the pri-
mary screening platform. Of these, three compounds (SN,
oleic acid [OA], and catechin hydrate [CH]) reproducibly
enhanced b-galactosidase activity significantly at both con-
centrations and were therefore chosen for further study.
For validation, these three compounds (Figure 1B) were
re-ordered and tested by serial dilution to generate efficacy
curves and to determine their half maximal effective con-
centrations (EC50). Consistently, these three hits enhanced
b-galactosidase activity in a dose-dependent manner. Two
hit compounds, SN and OA, showed effects at relatively
low effective concentration (SN, EC50 = 1.1 mM; OA,
EC50 = 1.1 mM), while the EC50 of CH was 10-fold higher
than the other two compounds (Figure 1C). When cells
were stained directly in situ, both SN and OA strongly
increased X-Gal staining (Figure 1D). However, CH failed
to enhance the X-Gal signal and was therefore not investi-
gated further.
SN Significantly Enhances Generation of CCS Cells
To rule out that the compounds were simply activating
expression of the CCS:lacz reporter gene, we used a second
CCS reporter line to examine the effect of SN and OA on
cardiac progenitors. Contactin2 (Cntn2) is specifically ex-
pressed in cells comprising the CCS of the mouse heart
including the SA node, AV node, His bundle, bundle
branches, and Purkinje fibers (Pallante et al., 2010). The
Cntn2:egfp line is derived from Cntn2:egfp BAC transgenic
mice that were shown to faithfully reproduce the endoge-
nous Cntn2 expression pattern (Pallante et al., 2010). A
full description and validation of this reporter line have
been reported recently (Maass et al., 2015). Again, growth
factor concentrations were defined using this ESC line to
promote a significant double-positive (FLK1+ and PDGFR-
a+) cell population, which was found to be similar as for
the CCS:Lacz line (Figure S1). The same differentiation pro-
tocol was used as for the primary screening (Figure 1A),
except that the cells were replated on gelatin-coated plates
at differentiation day 4 instead of day 5 to enhance the sur-
vival ofCntn2:egfp-derived cardiac progenitors. After 5 days
of treatment, SN orOAwere removed from themedia.Withhors
Figure 1. High-Throughput Screening and Characterization of Hit Compounds
(A) Scheme of high-throughput screen of CCS cell differentiation. CCS:Lacz ESCs were suspended in serum-free differentiation (SFD)
medium without cytokines for 2 days and allowed to form embryoid bodies (EBs). EBs were then dissociated and reaggregated in SFD
medium for 3 days with the defined cardiac mesoderm cytokine induction cocktail. At day 5, EBs were harvested and dissociated and cells
re-plated on gelatin-coated 384-well plates at a density of 5,000 cells/well in cardiomyocyte medium (RPMI with B27).
(B) Chemical structures of top hit compounds: sodium nitroprusside (SN), oleic acid (OA), and catechin hydrate (CH).
(C) Efficacy curves of SN, OA and CH. Error bars show SD.
(D) X-gal staining shows b-galactosidase expression under different doses of either SN or OA treatment, as indicated. DMSO was used as a
control. b-galactosidase expression is shown in blue.
Scale bar, 200 mm. See also Figure S1.this protocol, beating cell clusters were routinely observed
at differentiation day 7–8, and this was not obviously
affected by the addition of compounds. At differentiation
day 25, cells were co-stained using antibodies to GFP in
addition to the cardiac conduction marker HCN4. ByStem Cimmunofluorescence, both SN (Figure 2A) and OA (Fig-
ure S2A) highly increased the percentage of cells expressing
GFP and HCN4 compared to DMSO controls.
The percentages of HCN4+, Cntn2:EGFP+, and HCN4+/
Cntn2:EGFP+ double-positive cells were quantified byell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The Authors 1091
Figure 2. Sodium Nitroprusside Enhances Generation of Cardiac Conduction System Cells
(A) Expression of cardiac conduction system markers, HCN4 and Cntn2:EGFP, was examined by immunofluorescence staining using an-
tibodies against either HCN4 or GFP. Scale bar, 200 mm. DMSO was used as a control. Arrows indicate cells that are double positive deriving
from the SN-treated cultures.
(B) Quantification of immunofluorescence staining of HCN4+, Cntn2:EGFP+, and HCN4+/Cntn2:EGFP+ double-positive cells by MetaExpress
image analysis. Results represent the combined data from three independent differentiation experiments. Error bars show SD.
(C) Efficacy curve of SN in the Cntn2:egfp cell line. Results represent the combined data from three independent differentiation experi-
ments. Error bars show SD.
(D) Flow Cytometry analysis of Cntn2:EGFP expression. Following 5 days treatment of either SN or DMSO, cells were harvested at day 25 of
differentiation. Quantification of Cntn2:EGFP expression is shown in the right panel. Results are from five independent experiments. Error
bars show SD.
(E) SN- or DMSO-treated cells co-express cardiomyocyte markers aMHC or TNNT2 with Cntn2:EGFP. Cntn2:EGFP+ cells express relatively weak
levels of CX43 (right panel). Scale bar, 200 mm.
Asterisks indicate significant differences compared with DMSO. Statistical significance is indicated: *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S2.MetaExpress image analysis. SN significantly increased the
percentage of all three classes of cells in a dose-dependent
manner (Figure 2B) and with an EC50 of 9.7 mM for gener-
ation of Cntn2:EGFP+ cells (Figure 2C), which we note is
somewhat higher than found for LacZ expression using
the initial reporter line. While OA significantly enhanced1092 Stem Cell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The AutHCN4-expressing cells at 100 mM, it failed to increase either
Cntn2:EGFP+ or HCN4+/Cntn2:EGFP+ double-positive
cells (Figure S2A). Assessed by flow cytometry, SN increased
nearly 10-fold the percentage of Cntn2:EGFP+ cells at day
25 of differentiation (25.7% ± 7.6%) compared to DMSO
controls (2.6% ± 1.6%) (see representative plots inhors
Figure 3. SN-Induced Cntn2:EGFP+ Cells
Display a Purkinje-Fiber-like Action Po-
tential Phenotype
Cells from differentiated cultures that had
been induced with SN were evaluated in
patch-clamp studies. Cells were patched
from three independent differentiation
experiments.
(A) Representative stimulated AP traces
recorded in Cntn2:EGFP or Cntn2:EGFP+
cells.
(B) Comparison of action potential duration
(APD) 50 and 90 between GFP (n = 12) and
GFP+ cells (n = 8) (mean ± SE). Statistical
significance is indicated: **p < 0.01.Figure 2D). Cell cultures were also co-stained for the expres-
sion of cardiomyocyte markers: a myosin heavy chain
(aMHC), troponin T2 (TNNT2), and connexin 43 (CX43).
DMSO-treated cells expressed high levels of all three car-
diac markers but generated few Cntn2:EGFP+ cells (Fig-
ure 2E, upper panel), showing that the protocol efficiently
induced cardiomyocyte differentiation, as expected. In the
SN-treated cells, most of the GFP+ cells co-stained for cardi-
omyocyte markers, although many Cntn2:EGFP+ cells ap-
peared relatively low for levels of aMHC and TNNT2 (Fig-
ure 2E). In addition, the Cntn2:EGFP+ cells expressed
Cx43 at relatively weak levels compared to DMSO controls
(Figure 2E). These results suggest that SN can significantly
enhance the differentiation from cardiac progenitors to
cardiac conduction cell fate.
There are limitations to using these markers for reading
out CCS differentiation. Although the differentiation pro-
tocol should not promote neurogenesis, Cntn2 and Hcn4
are expressed in neurons as well as cardiac cells (DiFran-
cesco, 1985; Fain et al., 1978; Furley et al., 1990). Therefore,
it was important to rule out the possibility that SN was pro-
moting neural fate differentiation. After allowing cells to
undergo either spontaneous differentiation (which gener-
ates some differentiated neurons) or following the cardiac
differentiation including SN, cells were stained for expres-
sion of TUBB3, a neural marker (Burgoyne et al., 1988).
Many TUBB3+ cells were found in samples from ESCs un-
dergoing spontaneous differentiation (Figure S2B, left
panel), while in contrast, no Cntn2:EGFP+ or HCN4+ cells
co-stained as TUBB3+ cells (Figure S2B, right panel). To
further confirm this observation, we quantified the expres-
sion levels of additional neuronal genes, including Mash1,
Pax3, Sox3, and Tubb3, in RNA derived either from cells un-
dergoing spontaneous differentiation or from SN-induced
Cntn2:EGFP+ cells, using real-time qPCR. The results
confirmed that SN-induced Cntn2:EGFP+ cells do not ex-
press neural genes (Figure S2C). Thus, SN significantly en-
hances the generation of cells expressing CCS markersStem CHCN4 and CNTN2, and these HCN4+ and Cntn2:EGFP+
cells are not neural cells.
SN-Induced Cntn2:EGFP+ Cells Display a PC-like
Action Potential Phenotype
Cntn2:EGFP+ cells derived from the Cntn2:egfp reporter
ESC line were shown to display functional properties com-
parable to endogenous PC, including action potentials,
intracellular calcium cycling, and chronotropic behavior
(Maass et al., 2015). To confirm that these SN-induced
Cntn2:EGFP+ cells display the same functional PC pheno-
type, we used the whole-cell patch-clamp technique to
investigate their electrophysiologic properties. It has
been reported that PCs show a unique action potential
morphology and prolonged duration compared to ventric-
ular myocytes (Pallante et al., 2010). Hence, the action po-
tential durations were compared between Cntn2:EGFP
and Cntn2:EGFP+ cells from differentiation cultures that
had been induced with SN (Figure 3A). Although we did
not confirm with an independent reporter, all patched
cells from which action potentials were measured are car-
diomyocytes and presumably MHC positive. Compared
with GFP cells, the APD50 and APD90 values were found
to be increased in Cntn2:EGFP+ cells 2.5-fold and 2.0-
fold, respectively (Figure 3B), comparable to previously
reported differences between GFP and GFP+ cells differen-
tiated in the absence of SN (Maass et al., 2015). Also, the
action potential amplitude was slightly higher and the
maximal rate of rise (dV/dtmax) of the action potential
upstroke was greater in Cntn2:EGFP+ cells (Table S2).
Since there was no significant difference in the resting po-
tentials between GFP and GFP+ cells (Table S2), the faster
action potential upstrokes suggest higher sodium current
expression levels in GFP+ cells. These findings are consis-
tent with the biophysical properties of Purkinje cells (Vai-
dyanathan et al., 2013), suggesting that the differentiated
Cntn2:EGFP cells induced by SN treatment are PC-like
cells.ell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The Authors 1093
SN-Induced PC-like Cells Display Cardiac Conduction
System Gene Expression Profiles
To further characterize the phenotype of the SN-induced
EGFP+ cells, we measured the transcript profiles of known
cardiac-expressed genes in sorted cells. To distinguish car-
diac cells from non-cardiac cells in the GFP cell fraction,
we used a dual ESC reporter line harboring the Cntn2:egfp
transgene and transduced it with a lentiviral vector car-
rying the aMhc:mcherry reporter gene (Kita-Matsuo et al.,
2009). As shown previously (Maass et al., 2015), we could
use fluorescence-activated cell sorting (FACS) to separate
differentiating cultures into three cell populations: nega-
tive, aMhc:mCherry+ (GFP negative), and Cntn2:EGFP+.
We noted that this GFP+ cell population is also Cherry+,
although dim. Using stringent gating criteria, when
compared to DMSO-treated cells, SN consistently en-
hanced the generation of the Cntn2:EGFP+ (mCherry-
dim) cells, from 0.17% ± 0.1% to 38.3% ± 3.4% from three
independent experiments; a representative sort is shown in
Figure 4A.
We used qPCR to analyze the expression of cardiac con-
duction-associated genes in these three populations,
including genes that are reported to be associated with car-
diac conduction progenitors (Tbx3, Tbx5, Tbx18, Id2, and
Gata6), CCS channels (Hcn4, Cx30.2, Scn5a, Scn10a,
Cntn2, Cx40, Cav1.3, and Cav3.1), and cardiomyocyte
markers (Nkx2.5, Tnnt2, and Kir2.1). As expected, all of
these genes are expressed at significantly higher levels in
the aMhc:mCherry+ cells compared to the negative cells
(Figure 4B). Notably, all of the transcription factor genes
associated with cardiac conduction cells (Tbx3, Tbx5,
Tbx18, Id2, and Gata6) were expressed markedly higher
in the Cntn2:EGFP+ cells compared to expression levels
in the cardiac aMhc:mCherry+ cells. The same was true
for PC differentiation channels including Hcn4, Scn5a,
Scn10a, and Cntn2. Previous studies showed that Scn5a
transcripts are significantly enriched in PC (Maass et al.,
2015; Pallante et al., 2010). However, there was no signifi-
cant difference between these two populations for expres-
sion levels of the cardiac markerNkx2.5 (Figure 4B), consis-
tent with the PC-like cells retaining cardiac lineage fate.We
note that the GFP+ cells do express lower levels of some car-
diomyocyte transcripts, including Tnnt2, consistent with
the relatively low (dim) aMhc:mCherry profile. Kir2.1, nor-
mally expressed at high levels in working cardiomyocytes,
but not in CCS (Wolf and Berul, 2006; Zaritsky et al., 2001),
and the CCS channel Cav3.1 clearly distinguishes the two
cardiac cell phenotypes according to the qPCR results (Fig-
ure 4B). The transcript profiles of these three cell popula-
tions isolated from DMSO-treated control cells are very
comparable to the profiles obtained using SN-treated cells
(Figure S3). Notably, both DMSO-treated and SN-treated
GFP+ cells display 5- to 10-fold higher levels of Hcn4,1094 Stem Cell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The AutScn10a, Scn5a, andCx40 compared to the aMHC-mCherry+
(GFP) cardiomyocytes. Thus, SN treatment appears to
expand specifically the PC population that is present as a
rare cell type in the absence of SN.
To compare the gene expression profiles globally in these
cell populations, we performed RNA sequencing. The ex-
pression levels of genes in SN-induced aMhc:mCherry+
and Cntn2:EGFP+ (aMhc:mCherrydim) cells were normal-
ized with expression levels in negative cells. Next, the
gene list was filtered based on expression levels that are
10-fold different in Cntn2:EGFP+ cells. Hierarchical clus-
tering analysis revealed that the two cell populations are
much closer to each other compared to negative cells
(not shown) and that most of the differences (Figure 4C)
are upregulated in Cntn2:EGFP+ cells (90% are relatively
decreased in aMhc:mCherry+ cells). Subsequently, the
gene list was filtered based on expression levels that are at
least 5-fold higher in either aMhc:mCherry+ (898 genes)
or Cntn2:EGFP+ (918 genes). Venn diagram analysis
showed that among these filtered gene sets, Cntn2:EGFP+
cells shared relatively few genes with aMhc:mCherry+ cells
(127 genes; Figure 5A). Gene Ontology (GO) biological an-
alyses revealed that the genes expressed higher in aMhc:m-
Cherry+ single-positive cells are involved among various
processes in muscle tissue development and cardiac cell
development (Figure 5B), while those enhanced in the
EGFP+ cells are associated with cell responsive processes.
To assess which gene sets are enriched in the PC-like cells,
we performed gene set enrichment analysis (GSEA)
comparing gene sets with published microarray data. We
used two gene sets (GSE60987) in whichmouse PCs or ven-
tricular myocytes were isolated from adult compound
transgenic mice expressing Cntn2:EGFP and aMHC-Cre/
floxed tdTomato reporter genes (Kim et al., 2014). As ex-
pected, the gene set from aMhc:mCherry+ cells is enriched
in cardiomyocyte control samples (Figure 5C, left panel).
However, the gene set fromCntn2:EGFP+ cells is highly en-
riched in adult mouse PCs (Figure 5C, right panel), further
confirming that the SN-induced Cntn2:EGFP+ cells express
PC gene expression profiles.
SN Enhances ESC-Derived Cardiac Conduction Cell
Differentiation through Modulating the cAMP
Signaling Pathway
SN is known to be a short-acting parenteral arterial and
venous vasodilator. It has been shown that its effect is
through release of nitric oxide (NO) and activation of
guanylate cyclase (Friederich and Butterworth, 1995).
Moreover, SN has been shown to enhance cAMP levels
(Kim et al., 2006; Polte and Schro¨der, 1998). To test
whether SN acts to enhance CCS generation through a
cAMP signal, we directed Cntn2:egfp cells to cardiac fate
and challenged on day 5 with cAMP activators includinghors
Figure 4. SN Directs Cells to Express Cardiac Conduction System Markers
(A) FACS plots of Cntn2:EGFP+ and aMhc:mCherry+ populations using the aMhc: mcherry/Cntn2:egfp double reporter line. CCS:lacz cells were
used as negative control. Cells were harvested at differentiation day 25. FACS plots of negative, DMSO-, and SN-treated cells are shown in
the left, middle, and right panels, respectively.
(B) Cardiac conduction system gene expression profiles of three populations (negative, blue bars, normalized to 1; aMhc:mCherry+ [GFP
negative], red bars; Cntn2:EGFP+ [mCherry-dim], green bars) analyzed by qPCR. Comparison for significance of either mCherry+ or EGFP+ cell
populations with the negative population is indicated by asterisks (*). Comparison of Cntn2:EGFP+ cells with aMhc:mCherry+ cells are
shown by hashtags (#). Error bars show SD. Results are from three independent experiments.
(C) Hierarchical clustering analysis of significantly altered gene expression based on RNA sequencing from aMhc:mCherry+ and Cntn2:EGFP+
cells that were derived from differentiation cultures following induction with SN. aMhc, aMhc:mCherry+; Cntn2, Cntn2:EGFP+ cells.
Statistical significance is indicated: *p < 0.05, **p < 0.01, ***p < 0.001 and #p < 0.05, ##p < 0.01, ###p < 0.001. N.S. indicates not
statistically significant.
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Figure 5. ESC-Derived CCS Cells Display PC Gene Expression Profiling
(A) Venn diagram of gene sets at least 5-fold upregulated in aMhc:mCherry+ (GFP) or Cntn2:EGFP+ (mCherry-dim) populations.
(B) GO biological process analyses of the same gene sets.
(C) GSEA indicates that the restricted Cntn2:EGFP+ gene set is significantly enriched in adult mouse PC cells. A published dataset
(GSE60987) and the two gene sets that are >5-fold upregulated from aMhc:mCherry+ and Cntn2:EGFP+ populations were used. Enriched
gene sets are selected based on statistical significance (FDR q value < 0.25 and/or NOM p value < 0.05). Below are heat maps representing
enriched gene sets. High and low expression of the indicated genes in aMhc:mCherry+ and Cntn2:EGFP+ populations are represented in red
and blue, respectively. PC_1 and 2, two dataset of adult mouse PC cells; VM_1 and 2, two dataset of ventricular myocytes; aMhc,
aMhc:mCherry+; Cntn2, Cntn2:EGFP+ cells.
See also Figure S3.
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Figure 6. Sodium Nitroprusside Pro-
motes Generation of Cardiac Conduction
System Cells through cAMP Signaling
(A) A proposed mechanism of SN action.
cAMP activators and inhibitors are shown in
red and green, respectively.
(B) Quantification of the immunofluores-
cence staining of Cntn2:EGFP expression
by MetaExpress image analysis. Cells were
treated with cAMP activators (ZA, cAMP,
and FSK) or inhibitor (H89), respectively. A
blue column (DMSO control), pink column
(SN treatment), orange columns (cAMP ac-
tivators or inhibitors treatment), and pur-
ple columns (treatment of cAMP activators
or inhibitors combined with SN) are shown.
(C) Quantification of cAMP levels. Error bars
show SD. Comparison of either the activator
or the inhibitor treatments with DMSO
control is indicated by an asterisk (*).
Comparison of either activators or in-
hibitors combined with SN to the activators
or inhibitors itself is shown by a hashtag
(#). Results are derived from three inde-
pendent experiments.
Statistical significance is indicated: *p <
0.05, **p < 0.01, ***p < 0.001 and #p <
0.05, ##p < 0.01, ###p < 0.001.zardaverine (ZA), phosphodiesterase (PDE) inhibitor, dibu-
tyryl-cAMP, and forskolin (Figure 6A). Interestingly, all
cAMP activators significantly increased the generation of
Cntn2:EGFP+ cells (14.7 ± 0.6 for ZA, 9.3 ± 1.1 for dibu-
tyryl-cAMP, and 9.1 ± 1.2 for forskolin; fold change and
SD) compared with DMSO controls (1.3 ± 0.6 fold change
and SD; Figure 6B). We tested whether the cAMP activators
can synergize with SN to enhance cardiac conduction cell
fate and found that combining an individual activator
with SN significantly enhanced the percentage of cells
expressing Cntn2:EGFP compared with each activator
alone (20.0 ± 1.9 for ZA, 11.3 ± 1.3 for dibutyryl-cAMP,
and 12.8 ± 1.9 for forskolin; fold change and SD). A
cAMP inhibitor (H89; also protein kinase A inhibitor) was
also tested and found to abrogate the ability of SN to
enhance generation of Cntn2:EGFP+ cells (H89 + SN,
2.3 ± 1.2 versus SN, 10.4 ± 1.6; fold change and SD; Fig-
ure 6B). These data suggest that cAMP activators enhance
PC-like cell differentiation and that cAMP signaling is
required for the effect of SN.
The results suggest that SN may function entirely
through this pathway, since cAMP activators enhanced
Cntn2:EGFP+ cell generation comparably to SN. Therefore,
it was important to confirmwhether cAMP levels are in fact
increased by these treatments. During the cardiac differen-
tiation protocol, cells were treated at day 5 with SN, cAMPStem Cactivators, or cAMP inhibitors for 24 hr. Cells were har-
vested and the cAMP levels measured using a cAMP-Glo
assay (Figure 6C). SN significantly enhanced cAMP levels
compared to DMSO controls (17.9 ± 4.1 versus 2.4 ±
0.8 nM). As expected, all the cAMP activators also increased
cAMP levels (ZA: 30.9 ± 0.5 nM, cAMP:14.2 ± 2.5 nM, and
FSK: 17.9 ± 0.2 nM). Combining each activator with SN
enhanced approximately 2-fold levels of cAMP (ZA: 45.2
± 1.3 nM, cAMP: 31.8 ± 1.1 nM, and FSK: 35.2 ± 2.5 nM)
compared to treatments with SN or each activator alone.
On the contrary, H89 significantly blocked the ability of
SN to enhance cAMP levels (10.1 ± 2.7 versus 30.9 ± 0.5;
p < 0.005). The cAMP levels consistently correlated
with Cntn2:EGFP expression. Taken together, these data
support a model in which SN significantly enhances ESC-
derived cardiac conduction cell generation through activa-
tion of the cAMP signaling pathway.
SN-Induced Cntn2:EGFP+ Cells Are Derived from
Cardiomyocytes
The origin of CCS cell lineages remains an area of explo-
ration. Cell lineage studies in the embryonic chick heart
showed that Purkinje fibers can be differentiated from car-
diomyocytes (Cheng et al., 1999; Gourdie et al., 1995).
However, whether or not PC-like cells differentiate from
cardiomyocytes in ESC differentiation systems remainsell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The Authors 1097
Figure 7. SN-Induced Cntn2:EGFP+ Cells
Are Derived from Cardiomyocytes
Using the aMhc:mcherry/Cntn2:egfp double
reporter line, differentiated cells were
monitored from day 12 to day 17 of differ-
entiation. Images were taken every 4 hr.
Faint GFP+ cells are initially seen to
emerge from aMhc:mCherry+ cells at day 12
and were followed as GFP expression was
increased during 20 hr of culture. Shown
are representative panels from an experi-
ment that was reproducible in more than
three independent experiments. See also
Figure S4.unknown, although it is consistent with the co-expres-
sion of the aMhc:mCherry reporter. To investigate this
issue, we used the aMhc:mcherry/Cntn2:egfp double re-
porter line to monitor the emergence of differentiated
cells from day 12 to day 17 via live imaging. The aMhc:m-
Cherry+ (single-positive) cells could first be imaged at day
8, while the first Cntn2:EGFP+ cells did not emerge
until around day 12. Intriguingly, very faint GFP+ cells
were first observed coming from weakly fluorescent
aMhc:mCherry+ cells (Cherry-low), and these cells gradu-
ally over time generated a much stronger GFP signal (Fig-
ure 7A; Movie S1). Moreover, to further confirm the live
imaging data, a pure population of aMhc:mCherry+ cells
was sorted at early differentiation stage day 11 (Figure S4,
left panel) and placed back into culture. After 14 days,
Cntn2:EGFP+ (mCherry-dim) cells were generated from
these sorted aMhc:mCherry+ cells (Figure S4, right panel).
These data confirm that ESC-derived PC-like cells are
generated from cardiomyocytes.DISCUSSION
Directed differentiation protocols have been employed to
efficiently generate cardiomyocytes from both mouse and1098 Stem Cell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The Authuman ESCs (Kattman et al., 2011). However, it has re-
mained a challenge to efficiently generate CCS cells using
currently established protocols. In this study, we performed
a high-throughput screen and identified a small molecule,
sodium nitroprusside, which significantly enhances PC-
like differentiation efficiency up to 40% of the culture in
the context of a standard cardiac differentiation protocol.
SN was shown using two different CCS ESC reporter lines
to efficiently and reproducibly promote CCS cell genera-
tion. Using a aMhc:mcherry/Cntn2:egfp double reporter
line, it was possible to perform several complementary
comparisons to confirm that SN-treated cells represent a
PC-like lineage, including comparison of transcript and
protein profiles and action potential properties. Impor-
tantly, we found that SN promotes the generation of PC-
like cells by activating cAMP signaling, suggesting a key
pathway involved in embryonic derivation of the cardiac
Purkinje network. By monitoring the differentiation pro-
cess with live imaging and pre-sorting, we also demon-
strated that SN-induced Cntn2:EGFP+ cells are derived
from cardiac cells already expressing aMHC during ESC
differentiation.
There are no known transcription factors that are unique
to CCS or specifically PC fate. However, Tbx3, Tbx5, Tbx18,
Id2, and Gata6 are genes previously associated withhors
expression in CCS progenitors and derivatives. For in-
stance, Tbx3 can direct SA node specification and forma-
tion. Ectopic expression of Tbx3 in atria represses the atrial
phenotype and generates a pacemaker phenotype (Hoo-
gaars et al., 2007). Tbx5 is expressed in the AV bundle
and bundle branch, and in mice, Tbx5 haploinsufficiency
causes AV node maturation failure and abnormalities of
the bundle branch (Moskowitz et al., 2004). Tbx18 has
been shown to contribute to SA node formation (Wiese
et al., 2009). Id2 is expressed in AV bundle, and Id2-null
mice show left bundle branch block (Moskowitz et al.,
2007). While Gata6 is expressed throughout the devel-
oping heart, it becomes much more restricted in SA
and AV nodes as well as the AV bundle in the adult
mouse (Edwards et al., 2003). We found that SN-
induced Cntn2:EGFP+ cells expressed relatively higher
levels of these genes compared to cells that only express
aMhc:mCherry. Perhaps the best characterized marker for
PC is the Cntn2 gene, and Cntn2:EGFP+ cells that derive
from ESC differentiation have been described and func-
tionally characterized as displaying a PC phenotype (Maass
et al., 2015). Induction with SN provides a markedly
simple strategy to generate scalable numbers of these
otherwise rare cells. During live imaging, the EGFP+
cells were seen developing from cells that were already
aMhc:mCherry+, and they were also generated by further
culturing aMhc:mCherry+-sorted cells, indicating that
they derive from cardiac progenitors. Live imaging, flow
cytometry, and gene expression profiling data suggest
that the Cntn2:EGFP+ cells develop by downregulation of
the working cardiomyocyte program. We did not find
Cntn2:EGFP+ cells that were also aMhc:mCherry+high;
rather, they were all aMhc:mCherry+dim.
Notably, we found that SN enhances PC-like cell genera-
tion through the cAMP signaling pathway. Interestingly,
consistent with this mechanism, cAMP levels in the devel-
oping mouse heart increase through the b2-adrenergic re-
ceptor and adenylate cyclase type VI, which then leads to
the activation of the HCN4 channel (Biel et al., 2009).
Moreover, evidence has been presented to suggest that
cAMP can transform ventricular cardiomyocytes into pace-
maker-like cells (Ruhparwar et al., 2010; Sastry et al., 2006).
Thus, the findings presented here provide useful practical
information for developing new regenerative therapeutics
and also shed light on the normal process of CCS
development.EXPERIMENTAL PROCEDURES
ESC Culture and Differentiation
CCS:Lacz (Rentschler et al., 2001),Cntn2:egfp (Pallante et al., 2010),
and lentivirus-transduced aMhc:mcherry/Cntn2:egfp (Maass et al.,
2015) lines were maintained without feeder cells on 0.1%Stem Cgelatin-coated plate in serum-free conditions consisting of
DMEM/F12 (Gibco, 11320-33) and Neurobasal media (Gibco,
21103049) supplemented with N2 (Gibco, 17502-048), B27
(Gibco, 17504-044), BSA (Gibco, 15260-037), penicillin/strepto-
mycin, 1,000 U/ml ESGRO LIF (Millipore, ESG1107), 3 mM CHIR
99021 (Stemgent, 04-0004), 1 mM PD0325901 (Stemgent,
04-0006), 1.5 3 104 M MTG (Sigma), and 2 mM L-glutamine
(Gibco). Mediumwas changed every day. For SN-mediated cell dif-
ferentiation, ESCs were dissociated with Accutase and plated for
embryoid body (EB) formation (day 0) at 40,000 cells/ml in serum
free differentiation (SFD)mediumcomposed of 75% Iscove’smodi-
fied Dulbecco’s medium (Invitrogen) and 25% Ham’s F12 medium
(Invitrogen) supplementedwithN2, B27, penicillin/streptomycin,
0.05% BSA, 2 mM glutamine, 0.5 mM ascorbic acid (Sigma) and
0.1 mM b-mercaptoethanol (Gadue et al., 2006). After 48 hr, EBs
were dissociated with Accutase and reaggregated in SFD media
with the addition of human ACTIVIN-A (8 ng/ml), BMP4
(0.5 ng/ml), and VEGF (5 ng/ml) for another 48 hr. All cytokines
were purchased from R&D Systems. For experiments using the
double reporter line, at day 4, EBs were dissociated with Accutase
and replated at 58,000 cells/cm2 in 0.1% gelatin-coated six-well
plates with cardiomyocyte media containing RPMI (Corning cell-
gro, 10-041CV) with N2, B27 minus vitamin A (Life Technologies,
12587-010), penicillin/streptomycin, 2mMglutamine, 0.5mMas-
corbic acid, and 0.1 mM b-mercaptoethanol. The next day, differ-
entiated cells were treated with 100 mM SN for 5 days. Masterplex
ReaderFit software was used to generate the efficacy curves (EC50).High-Content Screening
CCS:Lacz ESCs were trypsinized and plated in SFD medium. After
48 hr, the EBs were dissociated with Accutase and reaggregated in
SFD medium with the addition of human ACTIVIN-A (8 ng/ml),
BMP4 (0.5 ng/ml), and VEGF (5 ng/ml). At day 5, EBs were dissoci-
ated with Accutase and replated at 5,000 cells per well in 0.1%
gelatin-coated 384-well plates with cardiomyocyte media. The
next day, cellswere treatedwith compounds from chemical libraries
in duplicate at either of two concentrations (10 mM or 1 mM). The
libraries include compounds from Sigma LOPAC (1,280 phar-
macologically active compounds, MicroSource US-Drug collection
(2,320 compounds, including known drugs, experimental bioactiv-
ities, and pure natural products, and the Prestwick Chemical library
(1,200 compounds, including 100% FDA-approved drugs). Cells
were harvested at day 11 to measure b-galactosidase activity, using
the Beta-Glo assay substrate (Promega, E4740). The effect of com-
pound on b-galactosidase activity was quantified by calculating
the fold induction, determined using the ratio A/B, where A repre-
sents the activity in the presence of compound and B represents
the activity in wells with only DMSO added. Hit compounds were
defined as those with A/B higher than 2.5. Hit compounds were
picked from the original library and validated in three independent
experiments using the same protocol.Real-Time qPCR
Total RNA from FACS-sorted cells was purified using the Absolutely
RNANanoprep kit (Agilent Technologies, 400753), quantifiedwith
a NanoDrop spectrophotometer (Thermo Scientific) and reverse
transcribed using a high-capacity cDNA reverse transcription kitell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The Authors 1099
(Applied Biosystems, 4374966). Real-time PCR was performed
with a LightCycler 480 (Roche) instrument with LightCycler
DNA master SYBR Green I reagents. Differences between samples
and controls were calculated based on the 2DDCT method (Livak
and Schmittgen, 2001) and normalized to GAPDH. Statistical
significance was determined using a two-tailed Student’s t test
(p < 0.05). Primer sequences are listed in Table S3.
Flow Cytometry and Immunohistochemistry
ESCs harboring the Cntn2:egfp and aMhc:mcherry reporter genes
have been described previously (Maass et al., 2015) and were
differentiated into cardiac and PC-like cells as described above.
At day 25, cells were dissociated with 1 mg/ml type II collagenase
(Life Technologies, 17101-015) and 20 U/ml DNase I (Millipore,
260913) for 40 min at 37C. Cells were centrifuged at
1,400 rpm for 4 min and resuspended in FACS buffer containing
DMEM without phenol red (Life Technologies, 21063-029), 1 mM
EDTA, 25 mM HEPES, and 5% fetal bovine serum (FBS). Cells
were collected using a BD FACSARIA cell sorter. For the flow anal-
ysis, approximately 50,000 single live-cell events were recorded
and analyzed per sample on a C6 flow cytometer (Accuri) and
analyzed using FCS express (De novo Software). For immuno-
staining, cells were fixed with 4% paraformaldehyde at room
temperature for 10 min and washed three times with 13 PBS.
Cells were then blocked with 5% horse serum and 0.3% Triton
X-100 and incubated with antibodies against HCN4 (1:500,
mouse; Abcam, ab85023), GFP (1:2,000, goat; R&D system,
AF4240), TNNT2 (1:500, mouse, Thermo Scientific, MA5-
12960), aMHC (1: 500, mouse, Abcam, ab15), Connexin43
(1:200, rabbit, ab11370), or TUBB3 (1:1,000, rabbit; Covance,
MRB-435) followed by Alexa-488-, Alexa-Fluor-555-, and Alexa-
Fluor-647-conjugated donkey secondary antibodies against
mouse, goat or Rabbit (1:500, Invitrogen). Nuclei were counter-
stained with DAPI.
Electrophysiology
Cells were dissociated and plated onto gelatin-coated coverslips
and then transferred into a recording chamber within 48 to
72 hr for whole-cell patch clamp studies. Cells were superfused
with Tyrode’s solution containing (mM) NaCl 137.7, KCl 5.4,
NaOH 2.3, CaCl21.8, MgCl2 1, Glucose 10, and HEPES 10 (pH
adjusted to 7.4 with NaOH) at room temperature. Electrodes
were filled with 50 mM KCl, 80 mM K-aspartic acid, 1 mM
MgCl2, 10 mM EGTA, 10 mM HEPES, and 3 mM Na2-ATP (pH
adjusted to 7.2 with KOH). The resistances of the electrodes were
between 2 and 3 MU. Only cells with gigaseal were used to collect
data. Stimulated action potentialswere triggered byminimumpos-
itive pulses with 1-Hz frequency with current clampmode. Signals
were recorded by an amplifier (MultiClamp 700B, Axon Instru-
ments) and a digitizer (Model DIGIDATA 1440A, Axon Instru-
ments) connected to a PC. Data acquisition and analysis were
performed using CLAMPEX 10.2 and CLAMFIT 10.2 software
(Axon instruments), respectively.
RNA Sequencing and Data Analysis
RNA was prepared from sorted cells with Absolutely RNA Nano-
prep kit. The cDNA libraries were generated using TruSeq RNA1100 Stem Cell Reports j Vol. 4 j 1089–1102 j June 9, 2015 j ª2015 The AutSample Preparation (Illumina). Each library was sequenced using
50-bp single reads in the HiSeq2500 format (Illumina). Raw data
were normalized with negative cells as a fold change. Gene lists
were analyzed with the Cluster software (Eisen et al., 1998). Hierar-
chical clustering involved Pearson correlation for population
comparisons and Euclidian distance calculations for gene level
clustering. Data were visualized with TreeView software (Eisen
et al., 1998). Global CCS and cardiomyocyte gene expression
data were obtained from a published database (GSE60987) (Kim
et al., 2014). False discovery rate (FDR) q values < 0.25 or nominal
(NOM) p values < 0.05 were considered significant.
cAMP Activity Determination
Day 4 EBs were dissociated and replated in 96-well plates. The next
day, differentiated cells were treated with activators, inhibitors, or
DMSO as control. Cells were harvested after 24-hr treatment. The
levels of cAMP activity were determined using the cAMP-Glo Kit
(Promega, V1501), according to the manufacturer’s instruction,
and using the EnVision automated microplate reader system
(Perkin Elmer).
Statistics
A two-tailed Student’s t test was used to calculate statistical
significance.
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